- Centers & Specialties
- Clinical Interests
- Ovarian cancer surgery
- Minimally invasive surgery
- Robotic surgery
- Personalized cancer therapy
- Medical Education
- MD, Vanderbilt University School of Medicine
- Residency, Brigham and Women's Hospital
- Fellowship, Brigham and Women's Hospital
- Board Certifications
- Obstetrics & Gynecology
- Gynecologic Oncology
- Boston: Massachusetts General Hospital
- Danvers: The Mass General/North Shore Center for Outpatient Care
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
Dr. Schorge was born and raised in mid-Michigan. He enrolled in the Honors Program at the University of Michigan, where he became a life-long Wolverines fan and met his future wife. He had a brief immersion in Southern culture during medical school at Vanderbilt University. Dr. Schorge next served an OB/GYN resident at the integrated Brigham & Women's Hospital-Mass General program before completing a gynecologic oncology fellowship at 'the Brigham'. He was on the faculty at the University of Texas Southwestern Medical School-Parkland Memorial Hospital in Dallas for eight years before returning to Boston as Chief of GYN Oncology at Mass General. Dr. Schorge has been married for 20+ years and has three children. He is a member of Red Sox Nation and the entire family proudly wear Tom Brady jerseys [U-Michigan alumnus].
- Research Summary
- Dr. Schorge's research interests primarily focus on ovarian cancer. He was the lead author on the 2010 Society of Gynecologic Oncology White Paper describing the etiology, screening and surveillance of this disease. He has spearheaded the investigation of the clinical benefits of cytoreductive surgery and incorporation of ultra-radical techniques to achieve prolonged survival for patients with advanced disease at Mass General - where the concept of aggressive debulking was initially described in the 1930s. He is co-Director of the the GYN ONC tissue repository where patient samples are tested for efficacy of novel treatments [under the supervision of Drs. Bo Rueda, Rosemary Foster and Whit Growdon]. Dr. Schorge is also a committee member of the Gynecologic Oncology Group and serves as the Principal Investigator at Mass General for a therapeutic GOG trial in patients with advanced ovarian cancer. His clinical experience and dedication to education is exemplified by his serving as the lead editor of Williams' Gynecology, a 1500+ page text with surgical atlas.
Schorge JO, Garrett LA, Goodman A. Cytoreductive surgery for advanced ovarian cancer: quo vadis? Oncology 2011;25:928-34.
Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Boruta DM 2nd, Horowitz NS, Del Carmen MG, Schorge JO. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol 2011 Oct 13.
Schorge JO, Bradford LS, del Carmen MG. Primary cytoreductive surgery for advanced ovarian cancer: is it the past, present, or future? Clin Adv Hematol Oncol 2011;9:912-8.
McCann CK, Growdon WB, Munro EG, Del Carmen MG, Boruta DM, Schorge JO, Goodman A. Prognostic significance of splenectomy as part of initial cytoreductive surgery in ovarian cancer. Ann Surg Oncol 2011;18:2912-8.
Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, Herzog TJ. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol. 2010;119:7-17.
Schorge JO, Wingo, SN, Bhore R, Heffernan TP, Lea JS. Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer. Int J Gynaecol Obstet. 2010;108:123-7.
One of the most serious health sequelae of obesity in women is the development of endometrial intraepithelial neoplasia (EIN) and later endometrial adenocarcinoma, attributed in part to the excess production of estrogen. In fact, the rising obesity rate accounts for a nearly 30% increase in the incidence and mortality rate of endometrial cancer over the past five years, in contrast to a general downtrend for other common malignancies.
The Collaborative Approach to Minimally Invasive Gynecologic Surgery (MIGS) at Mass General
The multidisciplinary Minimally Invasive Gynecologic Surgery (MIGS) Center includes specialized surgeons, fellows and a variety of other specialists. Our surgeons take a collaborative approach to patient care to determine the best procedure for each patient. Meet members of the MIGS team and hear one patient's story in this video by the American Congress of Obstetricians and Gynecologists (ACOG).
John Schorge, MD, discusses treatments for reproductive cancers
John Schorge, MD, chief of the Massachusetts General Hospital Gynecologic Oncology Division, discusses the types of treatment options available for patients with reproductive cancers.
55 Fruit Street
Yawkey Center for Outpatient Care
Boston MA, 02114-2696
104 Endicott Street
Danvers MA, 01923-3623